share_log

Galera Therapeutics Q3 EPS $(0.33) Beats $(0.40) Estimate; Cash, Cash Equivalents And Short-term Investments Of $28.4M Are Expected To Fund Its Operating Expenses And Capital Expenditure Requirements Into 2025

Benzinga ·  Nov 14, 2023 07:06

Galera Therapeutics (NASDAQ:GRTX) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.40) by 17.5 percent. This is a 45 percent increase over losses of $(0.60) per share from the same period last year.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment